Yocca Frank 4

What Happened
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics (BTAI), had 35 restricted stock units (RSUs) convert into 35 shares of common stock on June 15, 2026 (reported on Form 4). The filing also shows 35 shares were disposed at $0.00 — no cash proceeds were reported. This appears to be an administrative conversion/settlement of vested RSUs rather than an open-market sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (appears timely under the 2-business-day rule).
• Conversion: 35 RSUs -> 35 shares (acquired; price not applicable).
• Disposition: 35 shares disposed at $0.00 (derivative transaction reported as $0).
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Footnotes: F1 — each RSU converts to one share; F2 — these RSUs were part of a 562‑RSU grant on March 15, 2023 with a scheduled vesting cadence (25% at 1 year, then 6.25% every three months).
• No indication of a 10b5-1 plan or other sale plan in the disclosed excerpt.

Context
This transaction reflects conversion/settlement of vested RSUs. The $0.00 disposition line commonly represents share withholding or net-share settlement to satisfy tax obligations or administrative requirements, not a market sale for cash. Such RSU conversions and withholdings are routine and do not on their own imply a change in insider sentiment.